SYRE Spyre Therapeutics
- 27.650
- -0.780-2.74%
- 27.510
- -0.140-0.51%
Spyre Therapeutics News
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $71
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65
Spyre Therapeutics Is Maintained at Outperform by Baird
Spyre Therapeutics Analyst Ratings
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $70
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
Spyre Therapeutics Analyst Ratings
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Wells Fargo Issues a Buy Rating on Spyre Therapeutics (SYRE)
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Spyre Therapeutics Initiated at Outperform by Wedbush
Spyre Therapeutics Analyst Ratings
Analysis
Price Target
No Data
No Data